Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With M... | Not Recruiting
Long-Term Efficacy and Safety Exten... | Not Recruiting
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Mucopolysaccharidosis IV A
  • Morquio A Syndrome
  • MPS IVA
Unfortunately contact details are not available for this trial.
Primary Contact Details
Not Recruiting
Recruitment Status
NCT01415427
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
Research Details
  • This is a multi-center, multinational, extension study to evaluate 2 dose regimens of BMN 110 treatment in patients with MPS IVA who completed MOR-004.

    The last study visit assessments for MOR-004 will constitute Baseline for this study. The first study drug dose of this protocol will occur on Week 0 of MOR-005, which is the same as the last visit (Week 24) of MOR-004. Initially, the study will be double-blind with patients previously randomized to BMN 110 in MOR-004 remaining on their assigned BMN 110 dose regimen (qw or qow dosing). The MOR-004 placebo patients will be re-randomized (1:1 ratio) to one of the 2 BMN 110 dose regimen groups: 2.0 mg/kg/qw or 2.0 mg/kg/qow.

    There will be two study parts:

    - Part 1 - randomized double-blind until the optimal BMN 110 dose regimen has been determined, based on the final primary efficacy analysis from MOR-004

    - Part 2 - open-label BMN 110 treatment with the single optimal dose regimen
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : BMN 110 - Weekly, Drug : BMN 110 - Every Other Week

Study Arm Groups : BMN 110 Weekly, BMN 110 Every Other Week

Intervention Type
See Interventions above
Primary Outcome Measures
    Primary Long-Term Safety/Efficacy Evaluation; Approximately 240 weeks
Secondary Outcome Measures
    Long-Term evaluation of changes in biochemical markers of inflammation and bone and cartilage metabolism; Approximately 240 weeks
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
5 Years - N/A
Who Can Participate
Patients
Number of Participants
173
Participant Inclusion Criteria
    Inclusion Criteria:

    - Must have completed MOR-004

    - Is willing and able to provide written, signed informed consent. Or in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorize representative, after the nature of the study has been explained, and prior to performance of research-related procedures.

    - If sexually active, must be willing to use an acceptable method of contraception while participating in the study.

    - If female, of childbearing potential, must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests done during the study.

    Exclusion Criteria:

    - Is pregnant or breastfeeding, at Baseline, or planning to become pregnant (self or partner) at any time during the study.

    - Has used any investigational product (other than BMN 110 in MOR-004), or investigational medical device, within 30 days prior to Baseline; or is required to use any investigational agent prior to completion of all scheduled study assessments.

    - Was enrolled in a previous BMN 110 study, other than MOR-004.

    - Has a concurrent disease or condition, including but not limited to, symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation, or pose a safety risk, as determined by the Investigator.

    - Has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Local Institution
London
Greater London
Birmingham
B15 2TH
Manchester
Belfast
Birmingham
B4 6NH
University College of London, Institute of Neurology
London
WC1N 3BG
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Argentina, Brazil, Canada, Colombia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Norway, Portugal, Qatar, Saudi Arabia, Spain, Taiwan, United Kingdom, United States
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
MOR-005
Sponsor(s)
BioMarin Pharmaceutical
Key Dates

Recruitment Start Date

Jul 2011

Recruitment End Date

May 2017

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

08 Aug 2011

Last Updated

22 Apr 2014